U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Glioblastoma multiforme(GBM)

MedGen UID:
301585
Concept ID:
C1621958
Neoplastic Process
Synonym: GBM
SNOMED CT: Glioblastoma multiforme (393563007); Spongioblastoma multiforme (1163375002); Glioblastoma multiforme (1163375002); Glioblastoma (1163375002); GBM - glioblastoma multiforme (1163375002); GLM - glioblastoma multiforme (1163375002); Malignant glioblastoma (1163375002)
 
HPO: HP:0012174
OMIM®: 137800

Definition

A tumor arising from glia in the central nervous system with macroscopic regions of necrosis and hemorrhage. Microscopically, glioblastoma multiforme is characterized by regions of pseudopalisading necrosis, pleomorphic nuclei and cells, and microvascular proliferation. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGlioblastoma multiforme

Conditions with this feature

Glioma susceptibility 1
MedGen UID:
413414
Concept ID:
C2750850
Finding
Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, ependymomas, and subependymomas. Glial cells can show various degrees of differentiation even within the same tumor (summary by Kyritsis et al., 2010). Ependymomas are rare glial tumors of the brain and spinal cord (Yokota et al., 2003). Subependymomas are unusual tumors believed to arise from the bipotential subependymal cell, which normally differentiates into either ependymal cells or astrocytes. They were characterized as a distinct entity by Scheinker (1945). They tend to be slow-growing, noninvasive, and located in the ventricular system, septum pellucidum, cerebral aqueduct, or proximal spinal cord (summary by Ryken et al., 1994). Gliomas are known to occur in association with several other well-defined hereditary tumor syndromes such as mismatch repair cancer syndrome (see 276300), melanoma-astrocytoma syndrome (155755), neurofibromatosis-1 (NF1; 162200) and neurofibromatosis-2 (see SWNV, 101000), and tuberous sclerosis (TSC1; 191100). Familial clustering of gliomas may occur in the absence of these tumor syndromes, however. Genetic Heterogeneity of Susceptibility to Glioma Other glioma susceptibilities include GLM2 (613028), caused by variation in the PTEN gene (601728) on chromosome 10q23; GLM3 (613029), caused by variation in the BRCA2 gene (600185) on chromosome 13q13; GLM4 (607248), mapped to chromosome 15q23-q26.3; GLM5 (613030), mapped to chromosome 9p21; GLM6 (613031), mapped to chromosome 20q13; GLM7 (613032), mapped to chromosome 8q24; GLM8 (613033), mapped to chromosome 5p15; and GLM9, caused by variation in the POT1 gene (606478) on chromosome 7q31. Somatic mutation, disruption, or copy number variation of the following genes or loci may also contribute to the formation of glioma: ERBB (EGFR; 131550), ERBB2 (164870), LGI1 (604619), GAS41 (602116), GLI (165220), DMBT1 (601969), IDH1 (147700), IDH2 (147650), BRAF (164757), PARK2 (602544), TP53 (191170), RB1 (614041), PIK3CA (171834), 10p15, 19q, and 17p13.3.
Glioma susceptibility 3
MedGen UID:
442777
Concept ID:
C2751641
Finding
Any malignant glioma in which the cause of the disease is a mutation in the BRCA2 gene.
Mismatch repair cancer syndrome 1
MedGen UID:
1748029
Concept ID:
C5399763
Disease or Syndrome
Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.
Mismatch repair cancer syndrome 2
MedGen UID:
1750327
Concept ID:
C5436806
Disease or Syndrome
Mismatch repair cancer syndrome-2 (MMRCS2) is an autosomal recessive childhood cancer predisposition syndrome characterized by hematologic malignancy, brain tumors, and gastrointestinal tumors. Multiple cafe-au-lait spots reminiscent of neurofibromatosis type I (NF1; 162200) may be present. Microsatellite instability may be detected in tumor samples (Muller et al., 2006). For a discussion of genetic heterogeneity of mismatch repair cancer syndrome (MMRCS), see MMRCS1 (276300).
Mismatch repair cancer syndrome 3
MedGen UID:
1733656
Concept ID:
C5436807
Disease or Syndrome
Mismatch repair cancer syndrome-3 (MMRCS3) is an autosomal recessive childhood cancer predisposition syndrome characterized by brain tumors, hematologic malignancy, and gastrointestinal tumors. Multiple cafe-au-lait spots, axillary freckling, and, rarely, Lisch nodules reminiscent of neurofibromatosis type I (NF1; 162200) may be present (Hegde et al., 2005, Ostergaard et al., 2005). Microsatellite instability may be detected in tumor samples (Hegde et al., 2005). For a discussion of genetic heterogeneity of mismatch repair cancer syndrome, see MMRCS1 (276300).
Mismatch repair cancer syndrome 4
MedGen UID:
1745382
Concept ID:
C5436817
Disease or Syndrome
Mismatch repair cancer syndrome-4 (MMRCS4) is an autosomal recessive childhood cancer predisposition syndrome characterized by early-onset leukemia/lymphoma, brain tumors, colorectal/gastrointestinal cancers, and other rare malignancies, including rhabdomyosarcoma (summary by Li et al., 2015). Cafe-au-lait spots are usually present (De Vos et al., 2006). For a discussion of genetic heterogeneity of mismatch repair cancer syndrome, see MMRCS1 (276300).

Professional guidelines

PubMed

Czarnywojtek A, Borowska M, Dyrka K, Van Gool S, Sawicka-Gutaj N, Moskal J, Kościński J, Graczyk P, Hałas T, Lewandowska AM, Czepczyński R, Ruchała M
Pharmacology 2023;108(5):423-431. Epub 2023 Jul 17 doi: 10.1159/000531319. PMID: 37459849
Biserova K, Jakovlevs A, Uljanovs R, Strumfa I
Cells 2021 Mar 11;10(3) doi: 10.3390/cells10030621. PMID: 33799798Free PMC Article
Sordillo LA, Sordillo PP, Helson L
Anticancer Res 2015 Dec;35(12):6373-8. PMID: 26637846

Recent clinical studies

Etiology

Shoaib F, Furrukh M, Mushtaq F, Sayeed S, Nasir H, Ghafoor H
J Pak Med Assoc 2023 Sep;73(9):1869-1873. doi: 10.47391/JPMA.7694. PMID: 37817700
Afshari AR, Mollazadeh H, Henney NC, Jamialahmad T, Sahebkar A
Semin Cancer Biol 2021 Aug;73:116-133. Epub 2020 Aug 16 doi: 10.1016/j.semcancer.2020.08.002. PMID: 32814114
De Felice F, Pranno N, Marampon F, Musio D, Salducci M, Polimeni A, Tombolini V
Crit Rev Oncol Hematol 2019 Jun;138:60-69. Epub 2019 Apr 4 doi: 10.1016/j.critrevonc.2019.03.019. PMID: 31092387
Kerkhof M, Benit C, Duran-Pena A, Vecht CJ
CNS Oncol 2015;4(5):347-56. Epub 2015 Oct 19 doi: 10.2217/cns.15.29. PMID: 26478444Free PMC Article
Polyzoidis S, Ashkan K
Hum Vaccin Immunother 2014;10(11):3139-45. doi: 10.4161/hv.29276. PMID: 25483653Free PMC Article

Diagnosis

De Felice F, Pranno N, Marampon F, Musio D, Salducci M, Polimeni A, Tombolini V
Crit Rev Oncol Hematol 2019 Jun;138:60-69. Epub 2019 Apr 4 doi: 10.1016/j.critrevonc.2019.03.019. PMID: 31092387
Lewis MA
Oncologist 2019 Mar;24(3):421-422. Epub 2018 Nov 1 doi: 10.1634/theoncologist.2018-0720. PMID: 30867317Free PMC Article
Batash R, Asna N, Schaffer P, Francis N, Schaffer M
Curr Med Chem 2017;24(27):3002-3009. doi: 10.2174/0929867324666170516123206. PMID: 28521700
Luwor RB, Stylli SS, Kaye AH
J Clin Neurosci 2015 May;22(5):779-84. Epub 2015 Mar 26 doi: 10.1016/j.jocn.2014.11.001. PMID: 25816780
Polyzoidis S, Ashkan K
Hum Vaccin Immunother 2014;10(11):3139-45. doi: 10.4161/hv.29276. PMID: 25483653Free PMC Article

Therapy

Abrams DI, Velasco G, Twelves C, Ganju RK, Bar-Sela G
J Natl Cancer Inst Monogr 2021 Nov 28;2021(58):107-113. doi: 10.1093/jncimonographs/lgab010. PMID: 34850894
Mihelson N, McGavern DB
Viruses 2021 Jun 29;13(7) doi: 10.3390/v13071264. PMID: 34209584Free PMC Article
Doherty GJ, de Paula BHR
Br J Cancer 2021 Apr;124(8):1341-1343. Epub 2021 Feb 24 doi: 10.1038/s41416-021-01265-5. PMID: 33623077Free PMC Article
Lakomkin N, Hadjipanayis CG
J Surg Oncol 2018 Aug;118(2):356-361. Epub 2018 Aug 19 doi: 10.1002/jso.25154. PMID: 30125355
Huang B, Zhang H, Gu L, Ye B, Jian Z, Stary C, Xiong X
J Immunol Res 2017;2017:3597613. Epub 2017 Feb 19 doi: 10.1155/2017/3597613. PMID: 28299344Free PMC Article

Prognosis

Mohtashami E, Shafaei-Bajestani N, Mollazadeh H, Mousavi SH, Jalili-Nik M, Sahebkar A, Afshari AR
Curr Drug Metab 2020;21(8):564-578. doi: 10.2174/1389200221666200714101038. PMID: 32664839
Zhang X, Ding K, Wang J, Li X, Zhao P
Biomed Pharmacother 2019 Jan;109:39-46. Epub 2018 Nov 2 doi: 10.1016/j.biopha.2018.10.063. PMID: 30391707
Khan I, Waqas M, Shamim MS
J Pak Med Assoc 2017 May;67(5):816-817. PMID: 28507382
Sordillo LA, Sordillo PP, Helson L
Anticancer Res 2015 Dec;35(12):6373-8. PMID: 26637846
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL
Cancer Epidemiol Biomarkers Prev 2014 Oct;23(10):1985-96. Epub 2014 Jul 22 doi: 10.1158/1055-9965.EPI-14-0275. PMID: 25053711Free PMC Article

Clinical prediction guides

Harris DC, Mignucci-Jiménez G, Xu Y, Eikenberry SE, Quarles CC, Preul MC, Kuang Y, Kostelich EJ
Math Biosci Eng 2022 Mar 28;19(6):5446-5481. doi: 10.3934/mbe.2022256. PMID: 35603364
Afshari AR, Jalili-Nik M, Abbasinezhad-Moud F, Javid H, Karimi M, Mollazadeh H, Jamialahmadi T, Sathyapalan T, Sahebkar A
Curr Med Chem 2021;28(39):8116-8138. doi: 10.2174/0929867327666201111145212. PMID: 33176632
Lütgendorf-Caucig C, Freyschlag C, Masel EK, Marosi C
Curr Oncol Rep 2020 Jul 10;22(9):93. doi: 10.1007/s11912-020-00951-6. PMID: 32651730Free PMC Article
Rao AM, Quddusi A, Shamim MS
J Pak Med Assoc 2018 Jul;68(7):1137-1139. PMID: 30317322
Rutter EM, Banks HT, Flores KB
J Math Biol 2018 Dec;77(6-7):1999-2022. Epub 2018 May 8 doi: 10.1007/s00285-018-1238-6. PMID: 29737395

Recent systematic reviews

Kumari S, Gupta R, Ambasta RK, Kumar P
Biochim Biophys Acta Rev Cancer 2023 Jul;1878(4):188913. Epub 2023 May 12 doi: 10.1016/j.bbcan.2023.188913. PMID: 37182666
Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE
Pharmacol Res 2021 Sep;171:105780. Epub 2021 Jul 21 doi: 10.1016/j.phrs.2021.105780. PMID: 34302977Free PMC Article
Bastiancich C, Bozzato E, Henley I, Newland B
J Control Release 2021 Sep 10;337:296-305. Epub 2021 Jul 21 doi: 10.1016/j.jconrel.2021.07.031. PMID: 34298055
Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB
Cancer Invest 2014 Nov;32(9):451-7. Epub 2014 Sep 26 doi: 10.3109/07357907.2014.958234. PMID: 25259676
Theodotou C, Shah AH, Hayes S, Bregy A, Johnson JN, Aziz-Sultan MA, Komotar RJ
Br J Neurosurg 2014 Aug;28(4):438-46. Epub 2014 Jan 16 doi: 10.3109/02688697.2013.877122. PMID: 24432794

Supplemental Content

Table of contents

    Genetic Testing Registry

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...